Key insights
- Intellia Therapeutics presented positive Phase 3 HAELO trial data for its hereditary angioedema (HAE) treatment candidate, lonvoguran ziclumeran (lonvo-z). The data showed significant reductions in HAE attack rates and improvements in quality of life, with a high percentage of patients achieving complete attack control and becoming prophylaxis-free. The U.S. FDA has granted Priority Review for lonvo-z, with a target action date in March 2027. These results suggest strong potential for lonvo-z as a novel HAE therapy.
Intellia Therapeutics (Nasdaq: NTLA) presented clinical data for its hereditary angioedema (HAE) treatment candidate lonvoguran ziclumeran (lonvo-z) at the American College of Allergy, Asthma & Immunology 2026 Annual Scientific Meeting in Phoenix, Arizona.
Among patients in the Phase 3 HAELO trial who were on long-term prophylaxis (LTP) at study entry and randomized to the lonvo-z arm, the monthly HAE attack rate decreased by 81% following lonvo-z dosing compared with their rate while on prior LTP. Of those patients, 63% achieved complete attack control after treatment.
In an integrated analysis of 93 patients who received a single 50 mg dose of lonvo-z across Phase 1/2 and Phase 3 HAELO studies, the overall attack rate reduction from baseline was 89% through up to four years of follow-up, with 97% of patients never initiating LTP after treatment. All patients were LTP-free at the latest follow-up.
Across all prespecified HAELO subgroups, attack rate reductions favored lonvo-z over placebo regardless of disease severity or prior LTP use. All treatment-emergent adverse events in the lonvo-z arm were mild or moderate, with no serious adverse events observed.
In interviews with 23 Phase 1/2 patients, all reported their HAE as well controlled after receiving lonvo-z, compared with 48% before treatment. Of those, 22 patients (96%) described lonvo-z as an optimal therapy.
HAELO also met a key secondary endpoint measuring quality of life. Patients receiving lonvo-z had a 23.5-point mean reduction in Angioedema Quality of Life total score from baseline to week 28, compared with a 6.5-point reduction for placebo. A 6-point reduction is considered the threshold for a clinically important difference.
The U.S. Food and Drug Administration accepted a Biologics License Application for lonvo-z in September 2026, granting Priority Review with a PDUFA target action date of March 10, 2027.
That's one option. But ProPicks AI re-evaluates NTLA alongside thousands of other companies every month, using 100+ financial metrics, and it may have found you a better stock. ProPicks AI looks past headlines and Reddit to fundamentals, momentum and valuation. You get the rationale behind every pick, so you can check the logic before you act on it. Over three years, our strategies have returned 2.3X the S&P 500's returns. Find out whether NTLA made this month's lists, and which stocks in the same space did. Now 55% off for Black Friday early birds.